Tom 15, Nr 6 (2021)
Inne materiały uzgodnione z Redakcją
Opublikowany online: 2021-12-24

dostęp otwarty

Wyświetlenia strony 2900
Wyświetlenia/pobrania artykułu 89
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Bezsenność u osób w podeszłym wieku-możliwości leczenia w warunkach POZ

Paweł Wacław Królik1, Ewa Rudnicka-Drożak2
Forum Medycyny Rodzinnej 2021;15(6):253-262.

Streszczenie

Bezsenność jest zagadnieniem, które znajduje się poza głównym nurtem zainteresowań współczesnej medycyny. Ponieważ jest problemem interdyscyplinarnym, w praktyce bardzo często pozostaje w domenie lekarzy podstawowej opieki zdrowotnej. Jest jednym z wielkich zespołów geriatrycznych, z którym może spotkać się nawet 30-50 % osób w podeszłym wieku. Bezsenność niezwykle mocno pogarsza jakość ich życia będąc źródłem nie tylko zmęczenia, lęku i depresji, ale jest też związana z szeregiem innych dolegliwości i schorzeń oraz zwiększonym ryzykiem śmierci z przyczyn sercowo-naczyniowych. Jej rozpoznanie ma charakter kliniczny. Opiera się przede wszystkim na dokładnie zebranym wywiadzie. Terapia poznawczo-behawioralna, a więc edukacja, higiena snu, metody ograniczania snu i kontroli bodźców, jest podstawą leczenia bezsenności. Jej skuteczność jest porównywalna z leczeniem farmakologicznym, ale co istotne bez ryzyka działań niepożądanych. Jeśli istnieją trudności z wdrożeniem terapii poznawczo-behawioralnej lub nie prowadzi ona do złagodzenia objawów bezsenności, należy rozważyć zastosowanie leków nasennych.

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Patel D, Steinberg J, Patel P. Insomnia in the Elderly: A Review. J Clin Sleep Med. 2018; 14(6): 1017–1024.
  2. Buysse DJ. Insomnia. JAMA. 2013; 309(7): 706–716.
  3. Morin CM, LeBlanc M, Bélanger L, et al. Prevalence of insomnia and its treatment in Canada. Can J Psychiatry. 2011; 56(9): 540–548.
  4. Sateia M. International Classification of Sleep Disorders-Third Edition. Chest. 2014; 146(5): 1387–1394.
  5. Wennberg AM, Canham SL, Smith MT, et al. Optimizing sleep in older adults: treating insomnia. Maturitas. 2013; 76(3): 247–252.
  6. Bollu PC, Kaur H, Hepburn M, et al. Sleep and Parkinson Disease. Mo Med. 2017; 114(5): 381–386.
  7. Palagini L, Bruno RM, Gemignani A, et al. Sleep loss and hypertension: a systematic review. Curr Pharm Des. 2013; 19(13): 2409–2419.
  8. Troxel WM, Buysse DJ, Matthews KA, et al. Sleep symptoms predict the development of the metabolic syndrome. Sleep. 2010; 33(12): 1633–1640.
  9. Yaffe K, Falvey CM, Hoang T. Connections between sleep and cognition in older adults. Lancet Neurol. 2014; 13(10): 1017–1028.
  10. Javaheri S, Redline S. Insomnia and Risk of Cardiovascular Disease. Chest. 2017; 152(2): 435–444.
  11. Zheng B, Yu C, Lv J, et al. China Kadoorie Biobank Collaborative Group. Insomnia symptoms and risk of cardiovascular diseases among 0.5 million adults: A 10-year cohort. Neurology. 2019; 93(23): e2110–e2120.
  12. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017; 26(6): 675–700.
  13. https://www.sleepassociation.org/.
  14. Li J, Vitiello MV, Gooneratne NS. Sleep in Normal Aging. Sleep Med Clin. 2018; 13(1): 1–11.
  15. Moraes W, Piovezan R, Poyares D, et al. Effects of aging on sleep structure throughout adulthood: a population-based study. Sleep Med. 2014; 15(4): 401–409.
  16. Ohayon MM, Carskadon MA, Guilleminault C, et al. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep. 2004; 27(7): 1255–1273.
  17. Iwańczuk W, Guźniczak P. Neurofizjologiczne uwarunkowania procesów snu, czuwania, świadomości i przytomności. Część 2. Anestezjologia Intensywna Terapia. 2015; 47(2): 168–174.
  18. Dopheide JA. Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy. Am J Manag Care. 2020; 26(4 Suppl): S76–S84.
  19. Engelberth R, Pontes Ade, Fiuza F, et al. Changes in the suprachiasmatic nucleus during aging: Implications for biological rhythms. Psychology & Neuroscience. 2013; 6(3): 287–297.
  20. Benloucif S, Orbeta L, Ortiz R, et al. Morning or evening activity improves neuropsychological performance and subjective sleep quality in older adults. Sleep. 2004; 27(8): 1542–1551.
  21. Štefan L, Vrgoč G, Rupčić T, et al. Sleep Duration and Sleep Quality Are Associated with Physical Activity in Elderly People Living in Nursing Homes. Int J Environ Res Public Health. 2018; 15(11).
  22. Medrano-Martínez P, Ramos-Platón MJ. [Cognitive and emotional alterations in chronic insomnia]. Rev Neurol. 2016; 62(4): 170–178.
  23. van de Laar M, Verbeek I, Pevernagie D, et al. The role of personality traits in insomnia. Sleep Med Rev. 2010; 14(1): 61–68.
  24. Drake CL, Pillai V, Roth T. Stress and sleep reactivity: a prospective investigation of the stress-diathesis model of insomnia. Sleep. 2014; 37(8): 1295–1304.
  25. Mc Carthy CE. Sleep Disturbance, Sleep Disorders and Co-Morbidities in the Care of the Older Person. Med Sci (Basel). 2021; 9(2).
  26. Choi H, Youn S, Um YH, et al. Korean Clinical Practice Guideline for the Diagnosis and Treatment of Insomnia in Adults. Psychiatry Investig. 2020; 17(11): 1048–1059.
  27. Lichstein KL, Durrence HH, Taylor DJ, et al. Quantitative criteria for insomnia. Behav Res Ther. 2003; 41(4): 427–445.
  28. Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017; 13(2): 307–349.
  29. Qaseem A, Kansagara D, Forciea MA, et al. Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016; 165(2): 125–133.
  30. MacFarlane J, Morin CM, Montplaisir J. Hypnotics in insomnia: the experience of zolpidem. Clin Ther. 2014; 36(11): 1676–1701.
  31. Berry SD, Lee Y, Cai S, et al. Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Intern Med. 2013; 173(9): 754–761.
  32. French DD, Spehar AM, Campbell RR et al. Outpatient Benzodiazepine Prescribing, Adverse Events, and Costs. In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in Patient Safety: from Research to Implementation (Volume 1: Research Findings) Rockville, MD: Agency for Healthcare Research and Quality; 2005: 185–198.
  33. Schroeck JL, Ford J, Conway EL, et al. Review of Safety and Efficacy of Sleep Medicines in Older Adults. Clin Ther. 2016; 38(11): 2340–2372.
  34. Dailly E, Bourin M. The use of benzodiazepines in the aged patient: clinical and pharmacological considerations. Pak J Pharm Sci. 2008; 21(2): 144–150.
  35. Gunja N. The clinical and forensic toxicology of Z-drugs. J Med Toxicol. 2013; 9(2): 155–162.
  36. Bhandari P, Sapra A. Zaleplon. StatPearls [Internet] 2021. Treasure Island (FL): StatPearls Publishing;.
  37. Pinto LR, Bittencourt LR, Treptow EC, et al. Eszopiclone versus zopiclone in the treatment of insomnia. Clinics. 2016; 71(1): 5–9.
  38. Billioti de Gage S, Pariente A, Bégaud B. Is there really a link between benzodiazepine use and the risk of dementia? Expert Opin Drug Saf. 2015; 14(5): 733–747.
  39. Yi XY, Ni SF, Ghadami MR, et al. Trazodone for the treatment of insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. 2018; 45: 25–32.
  40. Generali JA, Cada DJ. Trazodone: Insomnia (Adults). Hosp Pharm. 2015; 50(5): 367–369.
  41. Jaffer KY, Chang T, Vanle B, et al. Trazodon for Insomnia: A Systemic Review. . Innov Clin Neurosci. 2017; 14(7-8): 24–34.
  42. Saletu B, Prause W, Anderer P, et al. Insomnia in somatoform pain disorder: sleep laboratory studies on differences to controls and acute effects of trazodone, evaluated by the Somnolyzer 24 x 7 and the Siesta database. Neuropsychobiology. 2005; 51(3): 148–163.
  43. Camargos EF, Louzada LL, Quintas JL, et al. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. Am J Geriatr Psychiatry. 2014; 22(12): 1565–1574.
  44. Fagiolini A, Comandini A, Catena Dell'Osso M, et al. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012; 26(12): 1033–1049.
  45. Krystal AD, Durrence HH, Scharf M, et al. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. Sleep. 2010; 33(11): 1553–1561.
  46. Karsten J, Hagenauw LA, Kamphuis J, et al. Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial. J Psychopharmacol. 2017; 31(3): 327–337.
  47. Jilani TN, Gibbons JR, Faizy RM et al. Mirtazapine. [Updated 2021 Aug 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK519059/ (1.01.2021).
  48. Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry. 2004; 6(Suppl 2): 3–7.
  49. Thompson W, Quay TAW, Rojas-Fernandez C, et al. Atypical antipsychotics for insomnia: a systematic review. Sleep Med. 2016; 22: 13–17.
  50. Modesto-Lowe V, Harabasz AK, Walker SA. Quetiapine for primary insomnia: Consider the risks. Cleve Clin J Med. 2021; 88(5): 286–294.
  51. Lee DO, Buchfuhrer MJ, Garcia-Borreguero D, et al. Efficacy of gabapentin enacarbil in adult patients with severe primary restless legs syndrome. Sleep Med. 2016; 19: 50–56.
  52. Liu GJ, Karim MdR, Xu LiLi, et al. Efficacy and Tolerability of Gabapentin in Adults with Sleep Disturbance in Medical Illness: A Systematic Review and Meta-analysis. Front Neurol. 2017; 8: 316.
  53. Fleet JL, Dixon SN, Kuwornu PJ, et al. Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population-based study. PLoS One. 2018; 13(3): e0193134.
  54. Gammoh O, Al-Smadi A, Shawagfeh MQ, et al. The Clinical Difference between Gabapentin and Pregabalin: Data from a Pilot Comparative Trial. Rev Recent Clin Trials. 2021; 16(3): 279–287.
  55. Wade AG, Crawford G, Ford I, et al. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response. Curr Med Res Opin. 2011; 27(1): 87–98.
  56. Rhyne DN, Anderson SL. Suvorexant in insomnia: efficacy, safety and place in therapy. Ther Adv Drug Saf. 2015; 6(5): 189–195.
  57. Owen RT. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia. Drugs Today (Barc). 2016; 52(1): 29–40.
  58. Norman JL, Anderson SL. Novel class of medications, orexin receptor antagonists, in the treatment of insomnia - critical appraisal of suvorexant. Nat Sci Sleep. 2016; 8: 239–247.
  59. Youn S, Choi B, Lee S, et al. Sleeping Pill Administration Time and Patient Subjective Satisfaction. J Clin Sleep Med. 2016; 12(1): 57–62.